~~<i id='8F0752ABD9'><strike id='8F0752ABD9'><tt id='8F0752ABD9'><pre id='8F0752ABD9'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

author：fashion 2025-09-06 04:30:08 - browse：483

Two business miniatures talk to each other on coin stacks that are sandwiched by a syringe and a stethoscope — coverage from STAT — Adobe

For all the flak they get, the country’s four biggest pharmacy benefit managers reported a surprisingly tame average profit margin in the first three quarters of 2023: 4.5%, less than a third of their drugmaker peers.

But don’t take their numbers as gospel, experts warned.

“It’s really easy to move money around inside the books of a vertically integrated organization,” said Karen Van Nuys, a senior fellow at the USC Schaeffer Center for Health Policy and Economics. “If one segment of your vertically integrated organization is not publishing any financial data, it’s a good place to hide stuff.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Why palliative psychiatry is worth discussing

hotspot

entertainment

focus

hotspot

TheonlytrialunderwayrightnowwilltestwhetheralongerregimenofPfizer’santiviralPaxlovidalleviatessympto

WSS

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Medicare inequities exacerbate Puerto Rico’s health disparities

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

New safety details link Apellis eye drug to rare cases of blindness

Vertex non

PBM reform efforts get punted in Congress

knowledge

knowledge

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

At least 13 dead in Texas as scorching temps continue

The Harvard botanist who searched for psychedelics in the Amazon

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Obesity drugs seen as possible treatment for liver disease MASH

Trump demands the U.S. pay no more for drugs than other countries … again

New safety details link Apellis eye drug to rare cases of blindness

Cancer drug shortages should be causing more outrage

EQRx, failed developer of low

entertainment

Sage hopes for a blockbuster in antidepressant now before FDA

Obesity drugs seen as possible treatment for liver disease MASH

Physician groups backed by private equity giant lobby on mergers

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

The Harvard botanist who searched for psychedelics in the Amazon

Lawsuit alleges UnitedHealth Group unit illegally denied claims

focus

focus

focus

hotspot